Sugi Predict

Sugi Predict / Compounds / SCHEMBL4257428

SCHEMBL4257428

SCHEMBL4257428

CC(C)(C)n1nc(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.42
▸ HTT P42858 3/20 0.41
▸ MAPT P10636 4/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ALDH1A1 P00352 5/20 0.39
▸ LMNA P02545 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ KDR P35968 2/20 0.38
▸ SRC P12931 1/20 0.38
▸ BRAF P15056 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ DHODH Q02127 1/20 0.37
▸ KDM1A O60341 1/20 0.37
▸ PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25901137 0.88 IKBKB (0.40) IKBKBHTTMAPTMEN1KMT2A
SCHEMBL25888754 0.85 HTT (0.41) IKBKBHTTMAPTMEN1KMT2A
SCHEMBL1318935 0.83 IKBKB (0.45) IKBKBHTTMAPTMEN1KMT2A
SCHEMBL25889014 0.83 HTT (0.42) IKBKBHTTMAPTMEN1KMT2A
SCHEMBL24133460 0.83 RIPK2 (0.39) HTTALDH1A1LMNAKDRSRC
SCHEMBL16263384 0.82 LMNA (0.38) HTTMAPTALDH1A1LMNAKDR
SCHEMBL25888804 0.82 RIPK2 (0.37) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL8308145 0.81 HPGD (0.49) HTTMAPTMEN1KMT2AALDH1A1
SCHEMBL15613500 0.80 ADORA1 (0.47) HTTMEN1KMT2AALDH1A1LMNA
SCHEMBL3691443 0.80 KDM4E (0.50) HTTMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 — — EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 — — US disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 — — EP disclosed
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-03-06 — — US disclosed
EP-4452966-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
US-20230227428-A1 AMIDO COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
US-20230227428-A1 AMIDO COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
WO-2023115149-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
EP-4168401-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-04-26 — — EP disclosed
CN-115956070-A Sulfonamide compounds 阿纳克西斯制药股份有限公司 2023-04-11 — — CN disclosed
WO-2021253095-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2021-12-23 — — WO disclosed
US-20090012309-A1 CHEMICAL COMPOUNDS ADAMS JERRY LEROY 2009-01-08 — — US disclosed
US-7307097-B2 Chemical compounds SMITHKLINE BEECHMAN CORPORATION (US) 2007-12-11 — — US disclosed
EP-1436265-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-12-15 — — EP disclosed
US-20040198986-A1 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-10-07 — — US disclosed
EP-1436265-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2004-07-14 — — EP disclosed
WO-2003072541-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP9 IKBKB 260/4885HTT 3355/4885MAPT 187/4885
US-20230227428-A1 AMIDO COMPOUNDS RIPK1, RIPK3, MLKL IKBKB 218/4885HTT 3476/4885MAPT 266/4885
US-20090012309-A1 CHEMICAL COMPOUNDS CYP11B2, CYP3A43, CYP3A5 IKBKB 2549/4885HTT 616/4885MAPT 1166/4885
US-12583836-B2 Sulphonamide compounds MLKL, RIPK3, CASP1 IKBKB 547/4885HTT 3278/4885MAPT 1287/4885
US-20230227429-A1 SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP1 IKBKB 188/4885HTT 3599/4885MAPT 165/4885
US-20040198986-A1 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors ERBB2, RET, ERBB4 IKBKB 727/4885HTT 3989/4885MAPT 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.